




PROGRAM

Wednesday 31 October

Wednesday 31 October				
PLENARY				
9:00am– 9:20am	Welcome to AusBiotech 2018 Queensland Government Representative Lorraine Chiroiu , Chief Executive Officer, AusBiotech			
9:20am– 10:00am	Keeping the balance in your clinical portfolio - prioritisation versus doing it all Dr Charmaine Gittleson , Chief Medical Officer, CSL Limited			
10:00am– 10:30am	Global life science investing & industry update John Carroll , Editor in Chief, Endpoints			
10:30am– 11:00am	Morning tea & networking with exhibitors in the exhibition hall			
	PLENARY	ROOM 1	ROOM 2	ROOM 3
11:00am– 12:30pm	Precision medicines: maintaining competitiveness in the post-human genome project era <i>This session will discuss the progression of precision medicines onto to the Australian market, implications for the industry & strategies to help Australian companies maintain global competitiveness in the post-human genome project era</i> Chair: Dr Anna Lavelle , Non-Executive Director, Medicines Australia Dr Lisette Pregeli , UQ Post-doctoral Research Fellow, The	The anatomy of a deal <i>This session provides valuable insights from a spectrum of stakeholders with experience in developing complex deals with multinationals in licensing, providing a service or a product</i> Chair: Dr Andrew Kelly , Executive Director, BioPacific Partners Panel: Dr Janette Dixon , Chief Executive Officer/Principal, BioComm Pacific Siddharth Shah , Director - External Innovations, Asia Pacific, Zoetis	<u>Regenerative Medicine Stream</u> A strategic view of the regenerative medicine landscape <i>This session will aim to explore the scientific & regulatory challenges related to progressing cell & gene therapies, highlighting recent scientific, regulatory & launch experience</i> Chair: Dr Tim Oldham , Executive Leader, Tijan Ventures Prof Ian Alexander , Head, Gene Therapy Research Unit, Children’s Medical Research Institute Prof Rajiv Khanna , Senior Scientist, QIMR Berghofer	<u>Agriculture & Agtech Stream</u> Gene technologies <i>‘GMO’ has been a disrupter in the way agriculture is produced but, with the advancement of gene editing technologies such as CRISPR, are GMOs now becoming redundant? New innovations in gene technologies & nanotech & current & future application in agriculture</i> Chair: Mike Pointon , General Manager Innovation & Development, Nufarm Ltd Prof Peter Waterhouse , Professor of Molecular Genetics, Science & Engineering Faculty,

	<p>University of Queensland Business School Assoc Prof Damian Hine, Strategy, The University of Queensland Business School Prof Karen Hussy, Director – Centre of Policy Futures, The University of Queensland Dr Rob Grenfell, Health Director, Health & Biosecurity, CSIRO Dr Peter Kambouris, Director, BD&C Health & Biosecurity, CSIRO</p>	<p>Dr Birgit Reitmaier, Head of Access to Innovation APAC, Merck</p>	<p>Dr Tim Farries, Director of Regulatory Affairs for Cell & Gene Therapy Products, ERA Consulting UK Lauren Carey, Oncology General Manager, Novartis Australia</p> 	<p>Earth, Environmental & Biological Sciences, Bioscience, Queensland University of Technology Prof Neena Mitter, Director, Centre for Horticultural Science, QAAFI, The University of Queensland Dr Tim Doran, Group Leader, CSIRO Health & Biosecurity</p> 
<p>12:30pm–1:30pm</p>	<p>Lunch & networking with exhibitors in the exhibition hall & AusBiotech Annual General Meeting in Room 1</p>			
	<p style="text-align: center;">PLENARY</p>		<p style="text-align: center;">ROOM 2</p>	<p style="text-align: center;">ROOM 3</p>
<p>1:30pm–1:45pm</p>	<p>Johnson & Johnson Innovation Industry Excellence Awards 2018</p> <ul style="list-style-type: none"> - <i>Industry Leadership Award</i> - <i>Australian Company of the Year</i> - <i>Australian Emerging Company of the Year</i> <p>Kathy Connell, Senior Director New Ventures, ANZ, Johnson & Johnson Lorraine Chiroiu, Chief Executive Officer, AusBiotech</p> 		<p>Regenerative Medicine Stream Australian regenerative medicine translation success stories: <i>Vignettes celebrating successful translation & commercialisation of these novel treatments by Australian companies with a focus on learnings</i> Chair: Silvio Tiziani, Chair Regenerative Medicine Advisory Group, AusBiotech Paul Anderson, Chief Executive Officer, Orthocell Prof Alan Trounson, Chief Executive Officer, Cartherics Craig Newton, Chief Executive Officer, Vivazome John Martin, CEO, Regeneus</p>	<p>Agriculture & Agtech Stream Agtech & big data <i>With big data comes big ideas. The challenge of agtech & science innovation will be to harness the output of the big data revolution. Exploring data capture, prediction & modelling systems for agriculture</i> Chair: Prof Bronwyn Harch, Deputy Vice-Chancellor (Research), The University of Queensland Prof Ben Hayes, Professorial Research Fellow, Centre for Animal Science, QAAFI, The University of Queensland</p>
<p>1:45pm–3:00pm</p>	<p>Big Pharma panel Chair: Lorraine Chiroiu, Chief Executive Officer, AusBiotech Ltd Panel: Liz Chatwin, Country President, AstraZeneca Aust/NZ Ben Thorner, Senior Vice President & Head of Business Development & Licensing, Merck Research Laboratories</p>			

Kathy Connell, Senior Director New Ventures, ANZ, Johnson & Johnson Innovation
Dr Anand Gautam, Senior Director & Head, External Science & Innovation, Australia, New Zealand & Southeast Asia, Pfizer
Dr Stephen Hitchcock, Head of Research, Takeda Pharmaceutical
Dr Elizabeth Kowaluk, Senior Director, Search & Evaluation, AbbVie

Prof Paul Simmons, Research & New Product Development, Mesoblast



Prof Guojie Zhang, Associate Director, China National GeneBank, BGI
Dr Nicole Jensen, General Manager, Genetics & Enabling Technologies, GRDC



3:00pm–3:30pm Afternoon tea & networking with exhibitors in the exhibition hall

	PLENARY	ROOM 1	ROOM 2	ROOM 3
3:30pm–5:00pm	<p>New gene technology in diagnostics, vaccines & CAR-T therapies Chair: Kylie Sproston, Chief Executive, Bellberry Limited Dr Michelle Fraser, CEO & Managing Director, Reproductive Health Science Limited Dr Tamara Cooper, SIEF STEM+ Research Fellow, Experimental Therapeutics Laboratory University of South Australia Cancer Research Institute Dr Janet Macpherson, Development Manager, Cell & Molecular Therapies, Royal Prince Alfred Hospital</p>	<p>Your company’s first IND: getting to and through FDA <i>This session is aimed at helping small teams successfully prepare for the process of building & submitting an IND & to establish a productive, collaborative relationship with FDA</i> Chair: Dr Andrea Douglas, Vice President, R&D Strategy & External Affairs, CSL Limited and Director, AusBiotech Dr Simone Flight, Senior Consultant, Clinical Network Services Anil Kane, Global Head of Technical & Scientific Affairs, Patheon Daniel Garcia, Senior Director, Biologics Business Management – Bioprocess Sciences Patheon</p>	<p>Regenerative Medicine Stream Building regenerative medicine industries – international perspectives <i>An account of how different countries are advancing their regenerative medicine activities, in particular the government and regulatory settings to support regenerative medicine advances</i> Chair: Sue MacLeman, Chair, MTPConnect Ltd Korea spotlight: Dr So Ra Park, Director/Professor, Strategic Center for Regenerative Medicine/Inha University Japan spotlight: Dr Yoshitsugu Shitaka, Vice Chairman, Forum for Innovative Regenerative Medicine (FIRM)</p>	<p>Agriculture & Agtech Stream Food & health <i>Recent achievements and future prospects in development & deregulation of GM foods for improved human health</i> Chair: Dr Allan Green, Innovation Leader, Agriculture & Food, CSIRO Dr James Petrie, Research Scientist, CSIRO Dist Prof James Dale, Professor, Institute for Future Environments, Qld University of Technology Prof Mike Gidley, Director, Centre for Nutrition & Food Sciences, QAAFI, The University of Queensland</p>



Israel spotlight:
Dr Shir Mnuchin, VP, Partnerships
 Connecting Industry, Academia &
 Government, Bioforum Ltd.
Canada spotlight:
Dr Michael May, President &
 Chief Executive Officer, CCRM
Belgium spotlight:
Roland Gordon-Beresford,
 Chief RA/IP Officer, Novadip
 Biosciences



5:00pm-5:30pm
 QAFFI networking event



5:30pm–
 7:00pm

AusBiotech 2018 welcome reception in the exhibition hall



Thursday 1 November

PLENARY

9:00am–
 9:40am

Millis Oration

Chair: Dr Andrea Douglas, Director, AusBiotech & Vice President, R&D Strategy & External Affairs, CSL Limited

The three pillars of WEHI's activities – science, translation & entrepreneurship

Prof Doug Hilton, Institute Director, Division Head of Molecular Medicine, Walter & Eliza Hall Institute



9:40am –
 9:45am



Minister Greg Hunt, Federal Member for Flinders & Minister for Health

Video presentation

PLENARY

ROOM 1

ROOM 2

<p>9:45am– 10:30am</p>	<p>Immunology/Oncology – recent advances <i>Now one of the major approaches in the treatment of cancer & autoimmune diseases. Remarkable clinical results with GM cellular therapies (CAR-T) & antibodies against immune checkpoints (CTLA-4, PD-1), have led to successful regulatory approval. The next phase of clinical development will include combination immunotherapies consisting of both cellular & antibody therapeutics. The panel will discuss the latest advances & how novel immunotherapeutic products can be progressed through developmental models & implemented in clinical settings</i></p> <p>Chair: Prof Rajiv Khanna, Senior Scientist, QIMR Berghofer</p> <p>Panel: Denis Patrick, VP of External Innovation & Science (oncology), Pfizer Dr Michael Rosenzweig, Executive Director, Tumor Immunotherapy, Merck Dr Goslik Schepers, Investment Manager, Brandon Capital Partners</p> 	<p>Early stage investment Oncology & stem cells presentations Chair: Glenn Cross, AusEvents Business Development Manager, AusBiotech</p> <p>Queensland ministerial speaker</p> <p>Precision epigenetics: silencing SMCHD1 to treat Prader-Willi Syndrome (PWS) - Walter & Eliza Hall Institute Novel Therapeutics for Parainfluenza - Institute for Glycomics, Griffith University Cell therapy for the treatment of peripheral artery disease– UniQuest, The University of Qld</p> 	<p>Gender diversity in Australian biotech <i>#metoo - A closer look at women in leadership positions, exploring how Australia measures up in terms of women in senior roles, questioning the progress & issues facing women in life sciences</i></p> <p>Chair: Sue Charles, Managing Partner, Instinctif Partners</p> <p>Panel: Stuart Roberts, Senior Analyst, NDF Research Samantha Cobb, Chief Executive Officer, AdAlta Dr Krystal Evans, Chief Executive Officer, BioMelbourne Network John Carroll, Editor in Chief, Endpoints Diana Sternfeld, Partner, Fieldfisher</p>
----------------------------	--	---	--

10.30am-11.00am Morning tea & networking with exhibitors in the exhibition hall

	PLENARY	ROOM 1	ROOM 2	ROOM 3
<p>11:00am– 12:30pm</p>	<p>Commercialising medicinal cannabis in Australia’s evolving regulatory environment</p>	<p>Early stage investment CNS, pain & vaccines presentations</p>	<p>From bench to bedside: GPCR drug discovery <i>Despite significant market size, over 80% of GPCR targets are yet</i></p>	<p>Clinical Trials Stream Harness the power of data for smarter drug development</p>

Medical cannabis is legalised in many countries & approved in Australia in late 2016. A number of medical conditions can be treated with cannabis extracts including chronic pain & chemotherapy nausea. There is patient confusion & frustration as the first companies navigate the complex regulatory environment & gain medical acceptance through doctor education. This session will outline the opportunity & progress in getting quality medical cannabis to Australian patient

Chair: Dr Stewart Washer, VP Business Development, Auscann
Elaine Darby, Chief Executive Officer, AusCann
Prof Cameron Scadding, Executive Chairman, Source Certain International
Emily Rigby, Director of Research Programs, Australian Institute for Medical Cannabis
Matt Spitzer, Program Coordinator, Oncology Clinical Trials, Mater Research

Chair: Glenn Cross, AusEvents Business Development Manager, AusBiotech
 Gene therapy approach for the treatment of Parkinson's disease - **Xynapse Therapeutics** Pty Ltd
 Small molecule therapeutics targeting neuroinflammation in Alzheimer's disease- **QEDDI, UniQuest**
 A novel approach for the treatment of painful diabetic neuropathy – **UniQuest, The University of Qld**
 Novel ion channel blockers for the treatment of pain - **Vast Bioscience Pty Ltd**
 DNA Vaccine for the treatment of Hepatitis C and HIV - **University of Adelaide**
 Novel Constructs for Flavivirus Vaccines – **UniQuest, The University of Qld**
 Molecular Clamp vaccine platform for RSV and influenza – **UniQuest, The University of Qld**
 The development of a hyperstable influenza vaccine- **James Cook University**



to be effectively exploited. This session will explore GPCRs in a number of therapeutic areas

Chair: Dr Angela Qu, Senior Director, Biomarker & Genomic Medicine, PAREXEL International
Samantha Cobb, Chief Executive Officer, AdAlta
Assoc Prof Kevin Pflieger, Chief Scientific Adviser, Dimerix Ltd
Dr Chris Langmead, Head, Servier Drug Discovery Program, Monash Institute of Pharmaceutical Services






Today, clinical trials are accommodating an incredible variety of data & content from various sources – from traditional clinical data, to high-resolution images, operational data & much more. As clinical trials become more complex, the biggest challenge for stakeholders is to reduce study risk, meet complex regulatory requirements, & reduce the life cycle of the clinical development without compromising the patient's experience

Chair: Eunho Shin, Head of Solution Consultant in APAC, Medidata
Mark Maclean, Head Clinical Data Management, NHMRC Clinical Trial Centre, University of Sydney
Dr Anthony Good, Vice President, Clinical Research, Imugene
Dr Thomas Polasek, Medical Director, Certara



12:30pm-1:30pm	Lunch & networking with exhibitors in the exhibition hall			
	PLENARY	ROOM 1	ROOM 2	ROOM 3

<p>1:30pm– 3:00pm</p>	<p>Accelerating the path from bench to biotech: focusing on entrepreneurship to drive innovation <i>The effect of building entrepreneurial capability in academic researchers has on transforming the innovation environment with a change in rate of research translation impact</i> Chair: Dougal Edwards, Chief Executive Officer, Bright Arena Panel: Prof Darren Kelly, Chief Executive Officer & Managing Director, Occurx Dr Rob Grenfell, Health Director, Health & Biosecurity, CSIRO Dr Kath Giles, Investment Manager, Brandon Capital</p>	<p>Early stage investment Oncology presentations Chair: Glenn Cross, AusBiotech N-NOSE: a new cancer screening innovation - Hirotsu Bio Australia Bi-specific antibodies for cancer immunotherapy- QIMR Berghofer MRI G9a inhibitors for the treatment of breast cancer- QIMR Berghofer MRI Adjuvant therapy for improved cancer treatment – UniQuest, The University of Qld Immune Checkpoint inhibitors - James Cook University First in class ion channel inhibitors for the treatment of cancer - QEDDI, UniQuest MelDX, a novel IVD test for detection of early stage melanoma - Edith Cowan University</p> 	<p>Digital Health: regulation & new technologies <i>A discussion of the rapid growth of new technologies in health care and approaches to their regulation</i> Includes: The Australia – China Life Sciences Partnership Program online launch Chair: Kim O’Connell, Partner, King & Wood Mallesons Panel: Anna Feros, Special Counsel, King & Wood Mallesons Dr Mike Skalsky, Managing Director, Sci2Rx Pty Ltd Brent Maxwell, Amazon Web Services Bronwyn Le Grice, Managing Director, ANDHealth Ltd</p> 	<p>Clinical Trials Stream Keys to winning clinical trial tenders in Australia <i>Discussing how to attract sponsors from a Central Lab prospective, the importance of strategic partnerships & attracting sponsors from a CRO prospective & presenting on facing the issue of our global location & turning it into a positive through planning (lane validation, packaging, transit times, infrastructure, population etc)</i> Chair: Dr Megan Robertson, Director of Research, St Vincent’s Hospital Panel: Brent McPherson, National Business Development Manager, World Courier Paulette Azar-Tannous, Chief Executive Officer, Sonic Clinical Trials Dr Michael Winlo, Chief Executive Officer, Linear</p> 
<p>3:00pm – 3:30pm</p>	<p>Afternoon tea & networking with exhibitors in the exhibition hall</p>			
	<p>PLENARY</p>	<p>ROOM 1</p>	<p>ROOM 2</p>	<p>ROOM 3</p>

3:30pm –
5:00pm

Curing paralysis – what innovations do we need to accelerate delivery of an effective therapy

Repairing a paralysed spinal cord has long been considered impossible, but now innovative technologies are now making this a reality. This session will highlight the demands & needs of the innovation pathway from patient through to advanced digital solutions

Chair: Assoc Prof James St John, Head, Clem Jones Centre for Neurobiology & Stem Cell Research, Griffith University
Perry Cross, Executive President, Perry Cross Spinal Research Foundation

Dr Brent McMonagle, ENT Surgeon, Gold Coast University Hospital

Assoc Prof James St John, Head, Clem Jones Centre for Neurobiology & Stem Cell Research, Griffith University
Genny Kroll-Rosen, Clinical Operations Manager, Making Strides

Prof David Lloyd, Chair, Gold Coast Orthopaedics Research & Education Alliance

**Early stage investment
Inflammation & immunology presentations**

Chair: Glenn Cross, AusBiotech

Novel complement modulators for the treatment of inflammatory and metabolic diseases – **UniQuest The University of Qld**

IL-22 conjugates for the treatment of NASH – **UniQuest, The University of Qld**

Rethinking CD52: a therapy for autoimmune disease - **Walter & Eliza Hall Institute**

Intercepting inflammation with RIPK2 inhibitors - **Walter & Eliza Hall Institute**

Reset and Maintenance, a novel approach to the treatment of autoimmune diseases - **Biomedicine Discovery Institute, Monash University**

HPGD2S inhibitors for asthma and allergic disease- **UniQuest, The University of Qld**



The anatomy of a clinical trials claim

A claim made by a patient suffering serious injury in a clinical trial can have a significant impact on the business sponsoring the trial. We will discuss what happens when a clinical trial insurance policy is called upon to respond to a demand for compensation from an injured trial participant. Hear from three experts, an insurance company, an insurance broking house & a legal firm

Chair: Estelle Smith, Life Science Manager, Australia & New Zealand, Chubb Insurance

Panel:
Scott Jordan, Senior Claims Technical Specialist, Chubb Insurance
Shane Aitken, Chief Operating Officer, Avatar Insurance Brokers
Karen Jones, Partner, Wotton & Kearney



**Clinical Trials Stream
Niche (neurological) clinical trial capabilities in Australia**

How we work with biotechnology companies to deliver their project
Chair: Dr Tina Soulis, Chief Executive Officer, Neuroscience Trials Australia

Dr Andrew Evans, Director of the Movement Disorders Service, Royal Melbourne Hospital

Prof Mark Cook, Chair of Medicine, St. Vincent's Hospital
Dr Nick Opie, Chief Technology Officer/Founder, Synchron Inc.
Dr Rebecca Sheean, Research Coordinator, Fight MND



7:00pm – 11:00pm Conference dinner at the Grand Chelsea Ballroom at the Mercure Brisbane Hotel



Friday 2 November

	PLENARY	ROOM 2
9:00am–10:00am	Investor session Chair: Lawrence Gozlan , Portfolio Manager, Scientia Capital Panel: John Carroll , Editor in Chief, Endpoint James leong , Head of IC – Chairman, Pagoda Investment Dr Sam Bakri , Global Entrepreneurs Programme UK	Artificial intelligence <i>The future of medical imaging and the basis and future of data mining and artificial intelligence</i> Chair: Dr Anna Lavelle , Non-Executive Director, Medicines Australia Dr Rowan Chapman , Head, Johnson & Johnson Innovation Prof Carolyn Mountford , Chief Executive Officer & Director of Research, Translational Research Institute Dr John Irvine , Chief Scientist for Data Analytics, Draper Laboratory Dr Nic Waddell , Group Leader of Medical Genomics, QIMR Dr David Hansen , Chief Executive Officer & Research Director, CSIRO e-Health Research Program
10:00am–10:30am	Update on Innovation & Science Australia Dr Charlie Day , Chief Executive Officer, Office of Innovation & Science Australia	
10:30am–11:00am	Morning tea & networking with exhibitors in the exhibition hall	
11:00am–12:30pm	Global life sciences outlook: leading in an era of unprecedented change <i>Gain insights on the 2019 outlook for life sciences from pharmaceuticals & biotechnology to diagnostics & digital health with key highlights from geographic, technology, competitive & customer perspectives</i> Chair: Glenn Cross , AusEvents Business Development Manager, AusBiotech	Creating investor value – recent Australian public company exits Chair: Megan Baldwin , Chief Executive Officer, Opthea Limited Rob Daniels , Chief Executive Officer, Elastagen Dr Tony Keating , CEO, ResApp David Blake , Founder, Bioshares Stuart Roberts , Founder & Senior Analyst, NDF Research

	<p>Mark Dougan, Consulting Director, Transformational Health, Frost & Sullivan Divya Chadha Manek, Head of Business Development, NIHR Clinical Research Network Dr Rowan Chapman, Head, Johnson & Johnson Innovation</p> <p style="text-align: center;">F R O S T  S U L L I V A N</p>	
<p>12:30pm– 2:30pm</p>	<p>Lunch, closing ceremony & handover to AusBiotech 2019 in the exhibition hall</p>	